GlassScriptPhysician profile
Amby J Bindra
NPI 1609831072
$858.57
in general payments reported to CMS, 2019-2025
15 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $348 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $173.13 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $159.84 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $103.03 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Cleerly, INC. | $86.57 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.39 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $50.43 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $50.31 | 2025 | |
| Pfizer INC. | $41.41 | 2025 | |
| Glaxosmithkline, LLC. | $35.81 | 2023-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $19.09 | 2024 | |
| Baxter Healthcare | $18.40 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $16.92 | 2025 | Prolia, Evenity |
| Antares Pharma, INC. | $16.41 | 2025 | Xyosted |
| Abbvie INC. | $15.05 | 2024 | |
| Renalytix Ai, INC. | $13.78 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amby Bindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.